NOT-HL-08-113: NHLBI Does Not Accept R21 Applications Primarily Related to Cancer Research

NHLBI Does Not Accept R21 Applications Primarily Related to Cancer Research

Notice Number: NOT-HL-08-113

Update: The following update relating to this announcement has been issued:

August 19, 2009 - See Notice NOT-HL-09-124 Clarification: NHLBI Does Not Accept R21 Applications Primarily Related to Cancer Research.

Key Dates
Release Date: March 6, 2008

Issued by
National Heart, Lung, and Blood Institute (NHLBI), (http://www.nhlbi.nih.gov/)

The purpose of this Notice is to advise investigators who plan to submit applications under the parent FOA (PA-06-181) for the NIH Exploratory/Developmental Research Grant (R21) award mechanism that the NHLBI does not accept the assignment of applications which focus primarily on cancer. Since there are some areas of overlapping interest, e.g., basic aspects of hematological malignancies resulting from disruptions in hematopoiesis, myeloproliferative and myelodysplastic disorders, or the use of hematopoietic stem cell transplantation and other cellular therapies, applicants are strongly encouraged to contact the NHLBI before submitting an application in response to this FOA .

Inquiries

Roy White, Ph.D.
Division of Extramural Research Activities
National Heart, Lung. and Blood Institute
National Institutes of Health
6701 Rockledge Drive
Room 7176, MSC 7956
Bethesda, MD 20892-7924
Telephone: (301) 435-0310
Fax: (301) 480-4755
Email: whiter@nhlbi.nih.gov

Nancy Difronzo, Ph.D.
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
National Institutes of Health
6701 Rockledge Drive
Room 9146, MSC 7950
Bethesda, MD 20892-7950
Telephone: (301) 435-0065
Fax: (301) 480-0868
Email: difronzon@nhlbi.nih.gov